Mederos L M, Valdivia J A, Valero-Guillén P L
Laboratorio Nacional de Referencias e Investigaciones de Tuberculosis y Micobacterias, Centro Colaborador OMS/OPS, Instituto de Medicina Tropical Pedro Kourí (IPK), La Habana, Cuba.
Tuberculosis (Edinb). 2006 May-Jul;86(3-4):324-9. doi: 10.1016/j.tube.2006.03.002. Epub 2006 Apr 24.
'Mycobacterium habana' was proposed as a distinct species within the genus Mycobacterium; however, it is actually a synonym of Mycobacterium simiae and included in the serotype I of this species. The potential use of 'M. habana' as a vaccine in both leprosy and tuberculosis has led to the analysis of its lipid composition in an attempt to define distinctive markers that could be used in the quality control of true strains of this bacterium. Lipids of taxonomic value (fatty and mycolic acids) are similar in 'M. habana' and M. simiae; nevertheless, they clearly differ on the basis of glycopeptidolipid (GPL) composition. Thus, contrary to M. simiae, most strains of 'M. habana' can be defined by the presence of three polar compounds, designated GPL-I, GPL-II and GPL-III, easily determined by thin-layer chromatography, and characterized, respectively, by the content of l-fucose, 2,4-di-O-Me-d-glucuronic acid, and 4-O-Me-d-glucuronic acid, as epitopes.
